Under CEO
Kevin Hykes, Relievant Medsystems is racking up some wins. The company closed on a $58 million Series E round last month and this week announced the first commercial application of its Intraspect pain-relief procedure. In this podcast, Hykes doles out some valuable career advice for wanna be CEOs and talks about the technology that could turn Relievant into a Medtech powerhouse.
Kevin Hykes
President & CEO
Relievant Medsystems
Kevin Hykes is the CEO and President of Relievant Medsystems, a privately held medical device company that has developed the Intracept® procedure, a breakthrough treatment for chronic lower back pain. Prior to Relievant, Kevin was an Operating Partner at Versant Ventures and Chairman and CEO of Metavention, Inc., a privately held medical device company focused on the development of interventional therapies for the treatment of type 2 diabetes. Kevin remains Chairman of the Board of Directors at Metavention. Prior to Metavention, Kevin was President and CEO of Cameron Health, developer of the subcutaneous implantable defibrillator, until its acquisition by Boston Scientific in 2012. Prior to Cameron Health, he was the Chief Commercial Officer of Visiogen, Inc., a privately held ophthalmology company which was acquired by Abbott Medical Optics in 2009. Previously, Kevin spent over sixteen years at Medtronic, where he held leadership positions in the CRM, Neurostimulation and Cardiac Surgery businesses in the US and Europe.
Kevin received his MBA from Northwestern University and a BBA from the University of Wisconsin. In addition to his role as Chairman of Metavention, Kevin serves as an independent board member at Veran Medical Technologies and the Courage Kenny Rehabilitation Institute Foundation.
